comparemela.com
Home
Live Updates
Eluminex Biosciences Acquires Zuretinol Acetate from Retinagenix Holdings : comparemela.com
Eluminex Biosciences Acquires Zuretinol Acetate from Retinagenix Holdings
Purchase of Assets and Related Global Commercialization Rights for Oral 9-cis-Retinol (Zuretinol) for Rare Forms of Childhood Blindness. Clinical ...
Related Keywords
University Of Washington ,
Washington ,
United States ,
Suzhou ,
Jiangsu ,
China ,
San Francisco Bay ,
California ,
Seattle ,
David Saperstein ,
Eluminex Biosciences ,
Charles Semba ,
Marco Northland ,
Retinagenix Holdings ,
Zuretinol Retinal Rare Pediatric Disease Program ,
Drug Administration ,
Program Has Received ,
Prnewswire Eluminex Biosciences Suzhou Limited ,
European Union ,
European Medicine Agency ,
Related Global Commercialization Rights ,
Rare Forms ,
Stage Asset Has Potential ,
First Approved Oral Therapy ,
Congenital Amaurosis ,
Retinitis Pigmentosa ,
Retinol Acyltransferase ,
Pediatric Disease ,
Fast Track Designation ,
Rare Pediatric Disease Priority Review ,
Zuretinol Include Treatment ,
Impaired Dark Adaptation ,
Night Blindness ,
Adult Patients ,
Early Dry Age Related Macular Degeneration ,
San Francisco Bay Area ,
Chief Medical Officer ,
Zuretinol Retinal Rare Pediatric Disease ,
Orphan Drug Designation ,
United States Food ,
Fast Track ,
Rare Pediatric Disease Priority Review Voucher ,
Priority Review ,
Nearly Dry ,
Suzhou Biobay Industrial Park ,
Lilly Asia Ventures ,
Hillhouse Capital ,
comparemela.com © 2020. All Rights Reserved.